Search results

Technologies 1

• Implantable Cancer Vaccine
  The implantable cancer vaccine is an aspirin-sized disc that is implanted under the skin and serves as an artificial lymph node, recruiting and training a patient's own immune cells to find and kill their cancer cells. It was validated in a Phase I clinical trial at the Wyss Institute, and is currently being developed by Novartis to treat melanoma.

Collaborations 1

• i3 Center: Biomaterials to Create T Cell Immunity
  Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.

News 12

View all

• Research Spotlights
  
  New cancer vaccine delivers double punch to tumors
  May 27, 2022
• Press Release
  
  Biomaterial vaccines ward off broad range of bacterial infections and septic shock
  July 8, 2021
• Research Spotlights
  
  Harvard “Immuno-engineering to Improve Immunotherapy” (i3) Center at the Wyss Institute awards first grant to Dana-Farber cancer immunologist Eric Smith
  January 21, 2021

Multimedia 1

• 

  Audio/Podcast
  Immunoengineering with Dave Mooney – BIOS Podcast
  Wyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They...